In this clinical case we report a fatal asthma episode in a 28-year old female, who was sensitized to pollens and mould, and with episodes of near-fatal asthma. She was successfully treated with omalizumab, that was discontinued after 5 years. After that, the patient also discontinued controller medications. In 2015, 3 years after omalizumab discontinuation, she had a fatal asthma attack, with respiratory failure and needing mechanical ventilation. This case report suggests that omalizumab treatment should not be discontinued in near-fatal asthma cases.
Fatal asthma after omalizumab and controller therapy discontinuation
Passalacqua, G
2018-01-01
Abstract
In this clinical case we report a fatal asthma episode in a 28-year old female, who was sensitized to pollens and mould, and with episodes of near-fatal asthma. She was successfully treated with omalizumab, that was discontinued after 5 years. After that, the patient also discontinued controller medications. In 2015, 3 years after omalizumab discontinuation, she had a fatal asthma attack, with respiratory failure and needing mechanical ventilation. This case report suggests that omalizumab treatment should not be discontinued in near-fatal asthma cases.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
volume-fatal-asthma-after-omalizumab-controller-1846allasp1.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
130.42 kB
Formato
Adobe PDF
|
130.42 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.